Live Updates: COVID-19 Cases
  • World 30,987,709
    World
    Confirmed: 30,987,709
    Active: 7,439,258
    Recovered: 22,587,048
    Death: 961,403
  • USA 6,967,403
    USA
    Confirmed: 6,967,403
    Active: 2,539,886
    Recovered: 4,223,693
    Death: 203,824
  • India 5,400,619
    India
    Confirmed: 5,400,619
    Active: 1,010,802
    Recovered: 4,303,043
    Death: 86,774
  • Brazil 4,528,347
    Brazil
    Confirmed: 4,528,347
    Active: 571,687
    Recovered: 3,820,095
    Death: 136,565
  • Russia 1,097,251
    Russia
    Confirmed: 1,097,251
    Active: 171,450
    Recovered: 906,462
    Death: 19,339
  • Peru 762,865
    Peru
    Confirmed: 762,865
    Active: 123,659
    Recovered: 607,837
    Death: 31,369
  • Mexico 694,121
    Mexico
    Confirmed: 694,121
    Active: 124,639
    Recovered: 496,224
    Death: 73,258
  • South Africa 659,656
    South Africa
    Confirmed: 659,656
    Active: 54,282
    Recovered: 589,434
    Death: 15,940
  • Spain 659,334
    Spain
    Confirmed: 659,334
    Active: 628,839
    Recovered: ?
    Death: 30,495
  • Chile 444,674
    Chile
    Confirmed: 444,674
    Active: 14,319
    Recovered: 418,101
    Death: 12,254
  • France 442,194
    France
    Confirmed: 442,194
    Active: 319,346
    Recovered: 91,574
    Death: 31,274
  • Iran 419,043
    Iran
    Confirmed: 419,043
    Active: 37,293
    Recovered: 357,632
    Death: 24,118
  • UK 390,358
    UK
    Confirmed: 390,358
    Active: 348,599
    Recovered: ?
    Death: 41,759
  • Bangladesh 347,372
    Bangladesh
    Confirmed: 347,372
    Active: 88,073
    Recovered: 254,386
    Death: 4,913
  • Saudi Arabia 329,271
    Saudi Arabia
    Confirmed: 329,271
    Active: 15,383
    Recovered: 309,430
    Death: 4,458
  • Pakistan 305,671
    Pakistan
    Confirmed: 305,671
    Active: 6,952
    Recovered: 292,303
    Death: 6,416
  • Turkey 301,348
    Turkey
    Confirmed: 301,348
    Active: 27,786
    Recovered: 266,117
    Death: 7,445
  • Italy 296,569
    Italy
    Confirmed: 296,569
    Active: 43,161
    Recovered: 217,716
    Death: 35,692
  • Germany 272,308
    Germany
    Confirmed: 272,308
    Active: 19,342
    Recovered: 243,500
    Death: 9,466
  • Canada 142,774
    Canada
    Confirmed: 142,774
    Active: 9,376
    Recovered: 124,187
    Death: 9,211
  • Netherlands 91,934
    Netherlands
    Confirmed: 91,934
    Active: 85,659
    Recovered: ?
    Death: 6,275
  • China 85,279
    China
    Confirmed: 85,279
    Active: 168
    Recovered: 80,477
    Death: 4,634
  • Australia 26,897
    Australia
    Confirmed: 26,897
    Active: 2,081
    Recovered: 23,967
    Death: 849
  • S. Korea 22,975
    S. Korea
    Confirmed: 22,975
    Active: 2,434
    Recovered: 20,158
    Death: 383
  • New Zealand 1,815
    New Zealand
    Confirmed: 1,815
    Active: 71
    Recovered: 1,719
    Death: 25

UK begins human trials for COVID-19 vaccine this week

Author at TechGenyz Health
Vaccine Trials
The Photograph Represents A Vaccine Trial On Humans. Credit: @nci/Unsplash

Clinical researchers began human trials this week of a new coronavirus vaccine developed by scientists at Imperial College London.

The study, which involves a set of people being immunised with the vaccine, will be the first time it has been trialled in humans and will test whether it is well-tolerated and produces an effective immune response against COVID-19.

“The COVID-19 pandemic has claimed thousands of lives and had a huge impact on daily life. In the long-term, a viable vaccine could be vital for protecting the most vulnerable, enabling restrictions to be eased and helping people to get back to normal life, said Professor Robin Shattock, from the Department of Infectious Disease at Imperial who is leading the work.

“From a scientific perspective, new technologies mean we have been able to get moving on a potential vaccine with unprecedented speed. We’ve been able to produce a vaccine from scratch and take it to human trials in just a few months from code to candidate which has never been done before with this type of vaccine.

“If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future, he said.

The researchers expect to publish findings once the safety data are available and are hopeful a viable vaccine could be available in the first half of 2021. They say the vaccine has undergone rigorous pre-clinical safety tests and in animal studies it has been shown to be safe and produced encouraging signs of an effective immune response.

Imperial College London said its vaccine candidate is being developed and trialled as a result of a 41-million pounds UK government funding and a further 5 million pounds in philanthropic donations.

It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases.

“The fast progress of Imperial’s vaccine is testament to the ingenuity and tenacity of Britain’s researchers. If these trials are successful, a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future,” said UK Business Secretary Alok Sharma.

Over the coming weeks, 300 healthy participants will receive two doses of the vaccine. If the vaccine is safe and shows a promising immune response in humans, then larger Phase III trials would be planned to begin later in the year with around 6,000 healthy volunteers to test its effectiveness.

Ultimately, the researchers hope that if clinical trials are successful, the vaccine could provide protection against COVID -19 both in the UK and around the world.

Dr Katrina Pollock, from Imperial’s Department of Infectious Disease and Chief Investigator of the study, said: These clinical studies are crucial in showing the safety of any new vaccine, and demonstrating the immune response it produces.

We need to assess whether the vaccine can train the immune system to defend itself against COVID-19. The vaccine can then be rolled out to more people in the UK and beyond in pivotal trials.

In the initial part of the study, the team will look to assess safety and find the optimal dose of the vaccine in 15 healthy participants aged 18 to 45 at a west London facility. The first participant will receive a very low dose of the vaccine, before the team escalates to increasingly higher doses for subsequent volunteers.

Following this initial small group, the team will then recruit further healthy volunteers (aged 18-75) to trial the optimal dose of vaccine in a larger population. The combined Phase I/II studies will aim to deliver the vaccine to a total of 300 people at the west London facility and additional sites.

All volunteers will receive two doses of the vaccine over two visits an initial dose and then a second boosting dose four weeks later.

Many traditional vaccines are based on a weakened or modified form of virus, or parts of it, but the Imperial vaccine is based on a new approach. It uses synthetic strands of genetic code (called RNA), based on the virus’ genetic material.

Once injected into a muscle, the RNA self amplifies generating copies of itself and instructs the body’s own cells to make copies of a spiky protein found on the outside of the virus. This should train the immune system to respond to the coronavirus so the body can easily recognize it and defend itself against COVID-19 in the future.

Kate Bingham, Vaccine Taskforce Chair, said: I am delighted that Imperial College have so quickly advanced to the clinical trial stage. Their self-amplifying technology has the potential to be a real game-changer, not only for a COVID-19 vaccine but for the development of future vaccines. It’s a great example of the world-leading life sciences sector in this country.

“By backing Imperial College London and their alternative vaccine platform, we have enhanced the UK’s vaccine portfolio, increasing our chances of identifying a successful vaccine.

Globally, more than 80 lakh people have tested positive for the virus ever since it was first reported in China last December, while more than 4.37 lakh have lost their lives. However, nearly 38 lakh have recovered too worldwide, according to the online COVID-19 tracker of Johns Hopkins University.

Career

Subscribe